Discovery of CDC42 Inhibitors with a Favorable Pharmacokinetic Profile and Anticancer In Vivo Efficacy-Reference-Cited by-同舟云学术

Discovery of CDC42 Inhibitors with a Favorable Pharmacokinetic Profile and Anticancer In Vivo Efficacy

Published:2024-06-12 Issue:12 Volume:67 Page:10401-10424
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Brindani Nicoletta¹,Vuong Linh M.²,La Serra Maria Antonietta¹^ORCID,Salvador Noel²,Menichetti Andrea¹,Acquistapace Isabella Maria¹^ORCID,Ortega Jose Antonio¹,Veronesi Marina³,Bertozzi Sine Mandrup⁴,Summa Maria⁵,Girotto Stefania³^ORCID,Bertorelli Rosalia⁵,Armirotti Andrea⁴^ORCID,Ganesan Anand K.²,De Vivo Marco¹^ORCID

Affiliation:

1. Molecular Modeling and Drug Discovery Lab, Istituto Italiano di Tecnologia, via Morego 30, 16163 Genova, Italy

2. Department of Dermatology, University of California, Irvine, California 92697, United States

3. Structural Biophysics Facility, Istituto Italiano di Tecnologia, via Morego 30, 16163 Genova, Italy

4. Analytical Chemistry Facility, Istituto Italiano di Tecnologia, via Morego 30, 16163 Genova, Italy

5. Translational Pharmacology Facility, Istituto Italiano di Tecnologia, via Morego 30, 16163 Genova, Italy

Funder

Associazione Italiana per la Ricerca sul Cancro

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00855

Reference50 articles.

1. Cdc42 overexpression induces hyperbranching in the developing mammary gland by enhancing cell migration

2. Molecular subversion of Cdc42 signalling in cancer

3. Could cell division cycle protein 42 be a target for lung cancer treatment?

4. Silencing of CDC42 inhibits neuroblastoma cell proliferation and transformation

5. Rho GTPase expression in tumourigenesis: Evidence for a significant link